Table 2 Systemic treatment management patterns per HR/HER2 status

Overall

HR⁺/HER2⁻

HR⁺/HER2⁺

HR⁻/HER2⁺

HR⁻/HER2⁻

Patients receiving first line treatment

N = 374

N = 188

N = 56

N = 43

N = 46

n (%)

n (%)

n (%)

n (%)

n (%)

Taxanes & Antiangiogenic agents

54 (14.4)

35 (18.6)

4 (7.1)

1 (2.3)

6 (13.0)

Aromatase inhibitors only

41 (11.0)

36 (19.1)

2 (3.6)

–

1 (2.2)

Platinum compounds & Taxanes & Antiangiogenic agents

19 (5.1)

5 (2.7)

–

–

13 (28.3)

Taxanes & Anti-HER2 agents

18 (4.8)

1 (0.5)

11 (19.6)

6 (14.0)

–

Pyrimidine analogues & Anti-HER2 agents

15 (4.0)

2 (1.1)

4 (7.1)

9 (20.9)

–

Other chemotherapy & Anti-HER2 agents

9 (2.4)

–

3 (5.4)

6 (14.0)

–

Patients receiving second line treatment

N = 254

N = 125

N = 36

N = 35

N = 33

n (%)

n (%)

n (%)

n (%)

n (%)

Aromatase inhibitors only

21 (8.3)

18 (14.4)

1 (2.8)

–

1 (3.0)

Anti-estrogens only

20 (7.9)

17 (13.6)

–

–

–

Aromatase inhibitors & mTOR inhibitors

20 (7.9)

17 (13.6)

–

–

2 (6.1)

Pyrimidine analogues & anti-HER2 agents

20 (7.9)

1 (0.8)

7 (19.4)

10 (28.6)

2 (6.1)

Anti-HER2 agents only

11 (4.3)

1 (0.8)

1 (2.8)

8 (22.9)

1 (3.0)

Other chemotherapy & Anti-HER2 agents

6 (2.4)

–

2 (5.6)

4 (11.4)

–

Platinum compounds & Pyrimidine analogues

6 (2.4)

1 (0.8)

–

–

4 (12.1)

Aromatase inhibitors & Anti-HER2 agents

6 (2.4)

–

6 (16.7)

–

–

Patients receiving third line treatment

N = 175

N = 89

N = 28

N = 24

N = 18

n (%)

n (%)

n (%)

n (%)

n (%)

Taxanes only

15 (8.6)

12 (13.5)

1 (3.6)

1 (4.2)

1 (5.6)

Pyrimidine analogues & Anti-HER2 agents

13 (7.4)

–

4 (14.3)

8 (33.3)

1 (5.6)

Pyrimidine analogues only

11 (6.3)

10 (11.2)

1 (3.6)

–

–

Aromatase inhibitors only

11 (6.3)

10 (11.2)

–

–

–

Anthracyclines & Other chemotherapy

7 (4.0)

4 (4.5)

–

1 (4.2)

2 (11.1)

Other chemotherapy & Anti-HER2 agents

6 (3.4)

1 (1.1)

3 (10.7)

1 (4.2)

1 (5.6)

Pyrimidine analogues & Antiangiogenic agents

5 (2.9)

2 (2.2)

–

–

3 (16.7)

Anti-HER2 agents only

5 (2.9)

–

–

5 (20.8)

–

Patients receiving beyond the third line treatment

N = 105

N = 49

N = 17

N = 18

N = 11

n (%)

n (%)

n (%)

n (%)

n (%)

Pyrimidine analogues only

6 (5.7)

5 (10.2)

1 (5.9)

–

–

Anti-estrogens only

5 (4.8)

5 (10.2)

–

–

–

Anthracyclines & Anti-HER2 agents

3 (2.9)

–

–

2 (11.1)

1 (9.1)

Other chemotherapy & Anti-HER2 agents

3 (2.9)

–

–

3 (16.7)

–

Pyrimidine analogues & Anti-HER2 agents

2 (1.9)

–

–

2 (11.1)

–

Pyrimidine analogues & Other chemotherapy & Anti-HER2 agents

2 (1.9)

–

–

2 (11.1)

–

Pyrimidine analogues & Taxanes & Other chemotherapy

2 (1.9)

–

–

–

2 (18.2)